Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review

References

• Van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-a, interleukin (IL)-1b and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-a and IL-1b. Br J Dermatol. 2011;164(6):1–4. doi:10.1111/j.1365-2133.2011.10254.x.
   Web of Science ®Google Scholar
• Matusiak Ł, Szczęch J, Bieniek A, et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670–675. doi:10.1016/j.jaad.2016.10.042.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434. Aug 4 PMID: 27518661. doi:10.1056/NEJMoa1504370.
   PubMed Web of Science ®Google Scholar
• Frew JW, Marzano AV, Wolk K, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2021;141(2):316–324.e2. doi:10.1016/j.jid.2020.06.019.
   PubMed Web of Science ®Google Scholar
• Navrazhina K, Frew JW, Grand D, et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol. 2022;187(2):223–233. Aug Epub 2022 Jun 2. PMID: 35191018; PMCID: PMC9356983. doi:10.1111/bjd.21060.
   PubMedGoogle Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761. Mar 4 doi:10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. PMID: 36746171.
   PubMed Web of Science ®Google Scholar
• Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, Placebo-Controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279–1288. Nov 1 Erratum in: JAMA Dermatol. 2021 Nov 1;157(11):1384. PMID: 34406364; PMCID: PMC8374742 doi:10.1001/jamadermatol.2021.2905.
   PubMed Web of Science ®Google Scholar
• Witte-Handel E, Wolk K, Tsaousi A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139(6):1294–1305. doi:10.1016/j.jid.2018.11.018.
   PubMed Web of Science ®Google Scholar
• Kashetsky N, Mufti A, Alabdulrazzaq S, et al. Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2022;26(1):79–86. Jan-Feb Epub 2021 Aug 8. PMID: 34365863. doi:10.1177/12034754211035667.
   PubMed Web of Science ®Google Scholar
• Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341–1348. Nov Epub 2020 May 13. PMID: 32416208; PMCID: PMC7572493. doi:10.1016/j.jaad.2020.05.007.
   PubMed Web of Science ®Google Scholar
• Tampouratzi E, Kanni T, Katsantonis J, et al. Case report: treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches. F1000Res. 2019;8:2002. Nov 26 PMID: 33456757; PMCID: PMC7791350. doi:10.12688/f1000research.21216.2.
   PubMedGoogle Scholar
• Frew JW, Navrazhina K, Sullivan-Whalen M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. Br J Dermatol. 2021;184(2):350–352. Feb Epub 2020 Sep 24. PMID: 32974912. doi:10.1111/bjd.19478.
   PubMed Web of Science ®Google Scholar
• Arenbergerova M, Arenberger P, Marques E, et al. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. Int J Dermatol. 2020;59(6):733–735. Jun Epub 2020 Feb 3. PMID: 32012238. doi:10.1111/ijd.14792.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Oyama N, Iino S, et al. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases. J Dermatol. 2021;48(6):916–920. doi:10.1111/1346-8138.15807.
   PubMed Web of Science ®Google Scholar
• Kearney N, Hughes R, Kirby B. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures - experiences from a specialty clinic. Clin Exp Dermatol. 2023;48(7):790–792. Apr 5:llad130. Epub ahead of print. PMID: 37017188. doi:10.1093/ced/llad130.
   PubMed Web of Science ®Google Scholar